Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +22.29%
#2 Ocean Protocol Ocean Protocol +18.64%
#3 KUB Coin KUB Coin +12.98%
#4 Audiera Audiera +10.79%
#5 Perle Perle +10.63%
#6 Wiki Cat Wiki Cat +9.96%
#7 Geodnet Geodnet +9.46%
#8 Arowana Arowana +9.35%
#9 OpenEden OpenEden +8.17%
#10 DexNet DexNet +7.78%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
MapLight Therapeutics, Inc. MapLight Therapeutics, Inc.

MapLight Therapeutics, Inc.

MPLT
Classement en actions #32256
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm... MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.
Prix de l'action
$13.43
Dernière synchronisation: 2026-07-31
Capitalisation boursière
$10.60M
Changement (1 jour)
-4.26%
Changement (1 an)
-
Pays
US
Échange MapLight Therapeutics, Inc. (MPLT)

Catégorie

Healthcare
Bénéfices pour MapLight Therapeutics, Inc. (MPLT)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de MapLight Therapeutics, Inc., les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour MapLight Therapeutics, Inc. de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR